Dr. Amanda Muir is a pediatric gastroenterologist at the Children’s Hospital of Philadelphia, where she is an Assistant Professor of Pediatrics. She earned a BA in Biology from Amherst College and then attending Rutgers-Robert Wood Johnson Medical School. She completed residency at Children’s Hospital of Philadelphia and stayed on to perform her fellowship in Gastroenterology, Hepatology and Nutrition. As a post-doctoral fellow, she completed her Masters in Translational Research. She completed the Consortium of Eosinophilic Gastrointestinal Disease Research Trainee Program. She is a member of the Center for Pediatric Eosinophilic Disorders which specializes in the care of patients with eosinophilic gastrointestinal disorders including Eosinophilic esophagitis as well as eosinophilic gastritis and enteritis.
The Muir Lab focuses on evaluating mechanisms of epithelial disruption and fibrosis in Eosinophilic esophagitis (EoE). The lab has pioneered a 3D ex vivo primary human organoid model of EoE and they are working on translational approaches to evaluate and treat esophageal fibrosis. She is the co-founder of the Gastrointestinal Epithelial Modeling Program which is a collaborative research effort designed to accelerate discovery and innovation using patient-derived organoids (PDO).
- Understand differences in Eosinophilic esophagitis disease presentation throughout childhood
Discuss the standard diagnostic and therapeutic strategies in Eosinophilic esophagitis
- Consider the challenges in detecting and treating patients with esophageal fibrosis from Eosinophilic esophagitis
This seminar was delivered as a Pediatric Grand Rounds Lecture at Children’s Hospital of Philadelphia, on September 21, 2022.
The work presented in the presentations, videos, and other content on this site (“Presentations”) includes publicly available medical evidence, a consensus of medical practitioners, and/or opinions of individual practitioners that may differ from consensus opinions. These Presentations are intended only to provide general information and need to be adapted for each specific patient based on the practitioner’s professional judgment, consideration of any unique circumstances, the needs of each patient and their family, the availability of various resources at the health care institution where the patient is located, and other factors. The Presentations are not intended to constitute medical advice or treatment, nor should they be relied upon as such. The Presentations are not intended to create a doctor-patient relationship between/among The Children’s Hospital of Philadelphia, its physicians and the individual patients in question. The information contained in these Presentations are general in nature, and do not and are not intended to refer to specific patients.
CHOP, The Children’s Hospital of Philadelphia Foundation and its or their affiliates, the authors, presenters, practitioners, editors, and others associated with the creation of the Presentations (“CHOP”) are not responsible for errors or omissions in the Presentations; for any outcomes a patient might experience where a clinician reviewed one or more such Presentations in connection with providing care for that patient; and/or for any and all third party content on the site or in the Presentations. CHOP makes no warranty, expressed or implied, with respect to the currency, completeness, applicability or accuracy of the Presentations. Application of the information in or to a particular situation remains the professional responsibility of the practitioner who is directly treating the patient.
To the extent that the Presentations include information regarding drug dosing, in view of ongoing research, changes in government regulations and the constant flow of information relating to drug therapy and drug reactions, the viewer should not rely on the Presentation content, but rather is urged to check the package insert for each drug for indications, dosage, warnings and precautions.
Some drugs and medical devices presented in the Presentations have United States Food and Drug Administration (FDA) clearance for limited use in restricted research settings. It is the responsibility of the practitioner to ascertain the FDA status of each drug or device planned for use in their clinical practice.
You shall indemnify, defend and hold harmless CHOP, The Children’s Hospital of Philadelphia Foundation, and its/their current and former employees, officers, and agents, trustees, and their respective successors, heirs and assigns (“Indemnitees”) against any claims, liability, damage, loss or expenses (including attorneys’ fees and expenses of litigation) in connection with any claims, suits, actions, demands or judgments arising directly or indirectly out of your reference to or use of the Presentations.
The Presentations are protected by copyright laws and in some cases patent laws, and all rights are reserved under such laws. No part of the Presentations may be reproduced in any form by any means, or utilized in any other way, absent prior written permission from the copyright owner.
By starting this module, you agree to our Content Disclaimer and Terms of Service.
CHOP Employee? Log In Here
**By selecting “Yes”, you consent to receive information from CHOP. Once you have decided to receive such communications, you may later decide to stop receiving these communications. If you want to stop receiving these communications, you may send an email message to email@example.com.